**AP) — The United States States is purchasing enough doses of a new twice-a-year HIV prevention shot to share with up to two million people in poor countries by 2028, the State Department announced Thursday.
Gilead Sciences had already announced it would sell that supply of the protective drug lenacapvir at no profit for use in low- and middle-income countries that are hard-hit by HIV.
The question was who would buy and distribute them after the Trump administration slashed foreign aid earlier this year – forcing closures of health clinics and disrupting HIV testing and care in many countries.
Under Thursday’s move, the US will purchase the doses under the PEPFAR programme and work with governments in hard-hit countries on how to distribute them.
The priority will be to protect pregnant or breastfeeding women, said Jeremy Lewin, a State department senior official.
We’re hoping, with the Global Fund, to help 2 million people get on the medication over the next three years but could potentially see more,” he said.
There are more than 30,000 new HIV infections in the US every year and 1.2 million people are living with the virus. Worldwide there are 1.3 million new infections annually and nearly 40 million people living with the virus.
Many experts say lenacapvir is the most powerful option yet for what’s called PrEP – using preventive medicines to guard against sexually transmitted HIV. Unlike daily pills that people may forget, each lenacapvir shot offers protection for six months. In two groundbreaking studies with people at high risk, it nearly eliminated new infections.
The drug already has been approved for use in the US and Europe.
